Bluefin Capital Management’s Quest Diagnostics DGX Stock Holding History

Bluefin Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,600	Closed	-$277K	–	736
2021 Q4	$277K	Sell	1,600 -670	-30%	-$102K	0.02%	478
2021 Q3	$330K	Buy	+2,270	New	+$332K	0.03%	369
2017 Q2	–	Sell	-8,700	Closed	-$854K	–	516
2017 Q1	$854K	Buy	+8,700	New	+$829K	0.11%	135
2016 Q3	–	Sell	-3,500	Closed	-$285K	–	471
2016 Q2	$285K	Buy	+3,500	New	+$267K	0.03%	253

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Bluefin Capital Management's DGX Position: Q1 2022 in Review

Bluefin Capital Management sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 1,600 shares — an estimated $277K sold.

Bluefin Capital Management first reported a position in DGX in Q2 2016 and held it in 4 quarters. The position peaked at $854K in Q1 2017. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

Bluefin Capital Management reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
Bluefin Capital Management sold 1,600 Quest Diagnostics shares in Q1 2022, an estimated $277K.
Bluefin Capital Management first reported a position in Quest Diagnostics in Q2 2016 and held it in 4 quarters.
Bluefin Capital Management's Quest Diagnostics position peaked at $854K in Q1 2017.
851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.